Silverfin false false 28/02/2025 01/03/2024 28/02/2025 S C G Black 22/08/2023 S Duguez 29/07/2024 22/08/2023 J Dumonceaux 22/08/2023 J A McLaren 22/08/2023 Dr V Ricotti 23/02/2023 O S Schafer 09/11/2023 E Vannier 22/08/2023 Professor T A Voit 22/08/2023 11 July 2025 no description of principal activity 14684070 2025-02-28 14684070 bus:Director1 2025-02-28 14684070 bus:Director2 2025-02-28 14684070 bus:Director3 2025-02-28 14684070 bus:Director4 2025-02-28 14684070 bus:Director5 2025-02-28 14684070 bus:Director6 2025-02-28 14684070 bus:Director7 2025-02-28 14684070 bus:Director8 2025-02-28 14684070 2024-02-29 14684070 core:CurrentFinancialInstruments 2025-02-28 14684070 core:CurrentFinancialInstruments 2024-02-29 14684070 core:ShareCapital 2025-02-28 14684070 core:ShareCapital 2024-02-29 14684070 core:SharePremium 2025-02-28 14684070 core:SharePremium 2024-02-29 14684070 core:OtherCapitalReserve 2025-02-28 14684070 core:OtherCapitalReserve 2024-02-29 14684070 core:RetainedEarningsAccumulatedLosses 2025-02-28 14684070 core:RetainedEarningsAccumulatedLosses 2024-02-29 14684070 core:ComputerEquipment 2024-02-29 14684070 core:ComputerEquipment 2025-02-28 14684070 bus:OrdinaryShareClass1 2025-02-28 14684070 bus:PreferenceShareClass1 2025-02-28 14684070 2024-03-01 2025-02-28 14684070 bus:FilletedAccounts 2024-03-01 2025-02-28 14684070 bus:SmallEntities 2024-03-01 2025-02-28 14684070 bus:AuditExemptWithAccountantsReport 2024-03-01 2025-02-28 14684070 bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 14684070 bus:Director1 2024-03-01 2025-02-28 14684070 bus:Director2 2024-03-01 2025-02-28 14684070 bus:Director3 2024-03-01 2025-02-28 14684070 bus:Director4 2024-03-01 2025-02-28 14684070 bus:Director5 2024-03-01 2025-02-28 14684070 bus:Director6 2024-03-01 2025-02-28 14684070 bus:Director7 2024-03-01 2025-02-28 14684070 bus:Director8 2024-03-01 2025-02-28 14684070 core:ComputerEquipment core:TopRangeValue 2024-03-01 2025-02-28 14684070 2023-02-23 2024-02-29 14684070 core:ComputerEquipment 2024-03-01 2025-02-28 14684070 bus:OrdinaryShareClass1 2024-03-01 2025-02-28 14684070 bus:OrdinaryShareClass1 2023-02-23 2024-02-29 14684070 bus:PreferenceShareClass1 2024-03-01 2025-02-28 14684070 bus:PreferenceShareClass1 2023-02-23 2024-02-29 14684070 1 2024-03-01 2025-02-28 iso4217:GBP xbrli:pure xbrli:shares

Company No: 14684070 (England and Wales)

VESALIC LIMITED

Unaudited Financial Statements
For the financial year ended 28 February 2025
Pages for filing with the registrar

VESALIC LIMITED

Unaudited Financial Statements

For the financial year ended 28 February 2025

Contents

VESALIC LIMITED

STATEMENT OF FINANCIAL POSITION

As at 28 February 2025
VESALIC LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 28 February 2025
Note 28.02.2025 29.02.2024
£ £
Fixed assets
Tangible assets 3 5,678 8,517
5,678 8,517
Current assets
Debtors 4 16,003 18,199
Cash at bank and in hand 1,348,081 2,084,484
1,364,084 2,102,683
Creditors: amounts falling due within one year 5 ( 78,941) ( 21,446)
Net current assets 1,285,143 2,081,237
Total assets less current liabilities 1,290,821 2,089,754
Net assets 1,290,821 2,089,754
Capital and reserves
Called-up share capital 6 13,801 13,801
Share premium account 3,131,047 3,131,047
Other reserves 10 866,196 0
Profit and loss account ( 2,720,223 ) ( 1,055,094 )
Total shareholders' funds 1,290,821 2,089,754

For the financial year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Vesalic Limited (registered number: 14684070) were approved and authorised for issue by the Board of Directors. They were signed on its behalf by:

Dr V Ricotti
Director

11 July 2025

VESALIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 28 February 2025
VESALIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 28 February 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial period, unless otherwise stated.

General information and basis of accounting

Vesalic Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the company's registered office is Flat 2 Discovery Dock Apartments East, 3 South Quay Square, London, E14 9RU, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The company made a loss in the year of £1,665,129 and has net current assets of £1,285,143 and net assets of £1,290,821 at the year end, including £1,348,081 of cash reserves. Subsequent to the year end a further £544,918 cash injection has been received taking the total value of shares issued post year end to £1,330,068. Therefore, at the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources, and access to additional funding if required, to continue in operational existence for the foreseeable future. Thus, the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Reporting period length

The comparative amounts in the financial statements are presented for the 12 month period from incorporation on 23 February 2023 up to 29 February 2024.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

Share-based payment

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black-Scholes valuation model. The fair value determined at the grant date is expensed over the vesting period in accordance with the vesting terms and based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

Option arrangement

Option arrangements are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black-Scholes valuation model. The fair value determined at the grant date is expensed over the vesting period in accordance with the vesting terms and based on the estimate of shares that will eventually vest. Option arrangements that meet the requirements are classified within equity.

Tangible fixed assets

Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment 3 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the statement of income.

Impairment of assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

The Company only enters into basic financial instruments and transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to and from related parties and investments in non-puttable ordinary shares.

Financial assets
Basic financial assets, including trade and other debtors are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Financial assets, other than those held at fair value through the statement of income, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in the statement of income.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in the statement of income.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities
Basic financial liabilities, including trade and other creditors and accruals, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2. Employees

Year ended
28.02.2025
Period from
23.02.2023 to
29.02.2024
Number Number
Monthly average number of persons employed by the company during the year, including directors 5 1

3. Tangible assets

Computer equipment Total
£ £
Cost
At 01 March 2024 8,517 8,517
At 28 February 2025 8,517 8,517
Accumulated depreciation
At 01 March 2024 0 0
Charge for the financial year 2,839 2,839
At 28 February 2025 2,839 2,839
Net book value
At 28 February 2025 5,678 5,678
At 29 February 2024 8,517 8,517

4. Debtors

28.02.2025 29.02.2024
£ £
Other debtors 16,003 18,199

5. Creditors: amounts falling due within one year

28.02.2025 29.02.2024
£ £
Trade creditors 72,666 15,874
Other taxation and social security 0 920
Other creditors 6,275 4,652
78,941 21,446

6. Called-up share capital

28.02.2025 29.02.2024
£ £
Allotted, called-up and fully-paid
1,260,097 Ordinary shares of £ 0.01 each 12,601 12,601
119,953 Preference non-redeemable shares of £ 0.01 each 1,200 1,200
13,801 13,801

7. Events after the Balance Sheet date

On 4 April 2025 the company issued 31,697 Ordinary shares for £17.35 per share and 44,964 Preference shares for £17.35 per share.

8. Share-based payment

The company operates a Company Share Option Plan under which certain employees of the company were granted share options under the terms of an approved Enterprise Management Incentive scheme. In the absence of observable market prices and market data, share options granted were valued at the fair value on the grant date using the Black Scholes valuation model and vest over a period of 3 years. The fair value of the options vested during the year is £7,805 and accordingly there is a share-based payment charge included in the profit and loss account in respect of these options.

At the start of the year there were nil options outstanding. During the year 8,000 (2023: nil) options were granted with a weighted average exercise price of £7.44. All of these options were outstanding at year end.

The share options can only be exercised if certain conditions are met on the event of a share sale, listing or other exit event of the company.

9. Option arrangement

The company has granted call options under which investors of the company are permitted to buy shares in the company. In the absence of observable market prices and market data, share options granted were valued at the fair value on the grant date using the Black Scholes valuation model and vest over a period of 2 to 3 years. The share option arrangements meet the requirements to be classified as equity. The fair value of the options have been spread over the vesting period and the fair value recognised in the year is £73,242. Accordingly there is a finance cost included in the profit and loss account in respect of these options.

At the start of the year there were nil options outstanding. During the year 34,594 (2023: nil) options were granted with a weighted average exercise price of £4.35. All of these options were outstanding at year end.

The share options can only be exercised if certain conditions are met on the event of a share sale, listing or other exit event of the company.

10. Reserves

28.02.2025 29.02.2024
£ £
Share-based payment reserve 7,805 0
Option arrangement reserve 73,242 0
Reserve for cash received from share issue after the balance sheet date 785,150 0
866,197 0